Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 650 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/31/10
End: 02/28/13
Due: 02/28/14
Phase: N/A
Priority: Normal
Start: 10/31/10
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/16/09
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/11/00
End: 02/25/19
Due: 02/25/20
Phase: N/A
Priority: Normal
Start: 01/31/95
End: 04/30/00
Due: 04/30/01
Phase: N/A
Priority: Normal
Start: 09/07/04
End: 08/11/14
Due: 08/11/15
Phase: N/A
Priority: Normal
Start: 09/30/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/06/12
End: 09/27/19
Due: 09/27/20
Phase: N/A
Priority: Normal
Start: 01/11/07
End: 04/24/13
Due: 04/24/14
Phase: N/A
Priority: Normal
Start: 01/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 01/27/11
End: 09/19/18
Due: 09/19/19
Phase: N/A
Priority: Normal
Start: 05/31/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/31/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 04/30/04
End: 04/30/08
Due: 04/30/09
Phase: N/A
Priority: Normal
Start: 10/21/21
End: 11/03/27
Due: 11/03/28
Phase: N/A
Priority: Normal
Start: 12/18/15
End: 02/16/17
Due: 02/16/18
Phase: N/A
Priority: Normal
Start: 11/30/06
End: 10/31/09
Due: 10/31/10
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
Phase: N/A
Priority: Normal
Start: 01/04/19
End: 02/18/21
Due: 02/18/22
Phase: N/A
Priority: Normal
Start: 10/31/06
End: 11/30/09
Due: 11/30/10
Phase: N/A
Priority: Normal
Start: 06/30/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/07
End: 07/31/09
Due: 07/31/10
Phase: N/A
Priority: Normal
Start: 10/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 08/31/07
End: 10/31/08
Due: 10/31/09
Phase: N/A
Priority: Normal
Start: 09/30/05
End: 06/30/06
Due: 06/30/07